Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7711076 | 1.00 | POLB (0.58) | POLBCYP2C9CYP2C19KMT2AAKR1C3 | |
| SCHEMBL16075922 | 1.00 | POLB (0.58) | POLBCYP2C9CYP2C19KMT2AAKR1C3 | |
| SCHEMBL1574429 | 0.89 | AKR1C3 (0.58) | POLBCYP2C9CYP2C19AKR1C3AKR1C2 | |
| SCHEMBL6344322 | 0.85 | POLB (0.55) | POLBCYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL1289928 | 0.85 | CYP2C9 (0.48) | POLBCYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL9588276 | 0.84 | FFAR2 (0.49) | POLBCYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL11471177 | 0.83 | AKR1C3 (0.66) | POLBCYP2C9CYP2C19AKR1C3AKR1C2 | |
| SCHEMBL23564521 | 0.82 | FFAR2 (0.48) | POLBCYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL27515059 | 0.82 | FFAR2 (0.48) | POLBCYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL27751810 | 0.82 | POLB (0.53) | POLBCYP2C9CYP2C19KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352498-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING PHENYLBUTYRATE AND METHODS THEREOF | AARDVARK THERAPEUTICS INC. (US) | 2025-11-20 | — | — | US | claimed |
| EP-4366739-A1 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2024-05-15 | — | — | EP | claimed |
| WO-2023279193-A2 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2023-01-12 | — | — | WO | claimed |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | ZGENE A/S (DK) | 2007-11-15 | — | — | US | claimed |
| WO-2005079849-A2 | COMPOUNDS FOR ENHANCED CANCER THERAPY | ZGENE A/S (DK) | 2005-09-01 | — | — | WO | claimed |
| US-5883124-A | ADMINISTERING PHENYLACETIC ACID DERIVATIVE AND RETINOID TO TREAT TUMORS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-03-16 | — | — | US | claimed |
| US-5843994-A | Compositions and methods for treating and preventing pathologies including cancer | THE UNITED STATES OF AMERICA AS REPRESENETED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-12-01 | — | — | US | claimed |
| US-5712307-A | Methods of inducing the production of hemoglobin and treating pathologies associated with abnormal hemoglobin activity using phemylacetic acids and derivatives therof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-27 | — | — | US | claimed |
| US-5710178-A | ARYL- AND ARYLOXYALKANOIC ACIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-20 | — | — | US | claimed |
| US-5708025-A | BY INDUCING PRODUCTION OF FETAL HEMOGLOBINS BY ADMINISTERING SPECIFIED ARYL ACIDS, DERIVATIVES, SALTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-13 | — | — | US | claimed |
| US-5661179-A | ADMINISTERING; TREATS NEUROBLASTOMA, MYELODYSPLASIA, NON-SMALL CELL LUNG CANCER, PROSTATE CANCER, MELANOMA, BRAIN TUMOR, KAPOSI'S SARCOMA, LYMPHOMA, LEUKEMIA, BREAST AND LUNG CANCER, OSTEOSARCOMA AND FIBROSARCOMA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-26 | — | — | US | claimed |
| US-5654333-A | THERAPY FOR ANEMIA, CANCER, AIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-05 | — | — | US | claimed |
| US-5635533-A | ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | claimed |
| US-5635532-A | ADMINISTERING PHENYL OR NAPHTHYL ACETIC ACID DERIVATIVES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | claimed |
| US-5605930-A | ADMINISTERING PHENYLACETIC ACID AS AN INHIBITOR OF THE MEVALONATE PATHWAY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-02-25 | — | — | US | claimed |
| EP-0537259-A1 | PROCESS FOR PRODUCING ENANTIOMERS OF 2-ARYL-ALKANOIC ACIDS | NOVO NORDISK A/S (DK) | 1993-04-21 | — | — | EP | claimed |
| US-5190946-A | Piperazine compounds restore sensitivity to drug resistant cancer cells | HOFFMANN-LA ROCHE INC. (US) | 1993-03-02 | — | — | US | claimed |
| WO-1992001062-A1 | PROCESS FOR PRODUCING ENANTIOMERS OF 2-ARYL-ALKANOIC ACIDS | NOVO NORDISK A/S (DK) | 1992-01-23 | — | — | WO | claimed |
| EP-0443569-A2 | Diamine derivatives and their use in oncology | F. HOFFMANN-LA ROCHE AG (CH) | 1991-08-28 | — | — | EP | claimed |
| US-20250352498-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING PHENYLBUTYRATE AND METHODS THEREOF | AARDVARK THERAPEUTICS INC. (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250295652-A1 | Inhibitors of Molluscum Contagiosum Infection and Methods Using the Same | UNIV PENNSYLVANIA (US) | 2025-09-25 | — | — | US | disclosed |
| CN-118541359-A | Inhibitors of molluscum contagiosum infection and methods of use thereof | 宾夕法尼亚大学董事会 | 2024-08-23 | — | — | CN | disclosed |
| EP-4408833-A1 | INHIBITORS OF MOLLUSCUM CONTAGIOSUM INFECTION AND METHODS USING THE SAME | The Trustees of The University of Pennsylvania (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20240246904-A1 | FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2024-07-25 | — | — | US | disclosed |
| US-11873267-B2 | Functionalized N,N-dialkylamino phenyl ethers and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873267-B2 | Functionalized N,N-dialkylamino phenyl ethers and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873267-B2 | Functionalized N,N-dialkylamino phenyl ethers and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2023049919-A1 | INHIBITORS OF MOLLUSCUM CONTAGIOSUM INFECTION AND METHODS USING THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20200392073-A1 | NOVEL FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-12-17 | — | — | US | disclosed |
| US-20200392073-A1 | NOVEL FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-12-17 | — | — | US | disclosed |
| EP-3717480-A1 | METHOD FOR PRODUCING (3S)-3-(4-CHLOR-3-{[(2S,3R)-2-(4-CHLORPHENYL)-4,4,4-TRIFLUOR-3-METHYLBUTANOYL]AMINO}PHENYL)-3-CYCLO-PROPYLPROPANOIC ACID AND THE CRYSTALLINE FORM THEREOF FOR USE AS A PHARMACEUTICAL INGREDIENT | Bayer Pharma Aktiengesellschaft (DE) | 2020-10-07 | — | — | EP | disclosed |
| WO-2017205451-A1 | NOVEL FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205451-A1 | NOVEL FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-11-30 | — | — | WO | disclosed |
| US-9061040-B2 | Combination therapy for breast cancer | CIUSTEA MIHAI (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150094277-A1 | Combination therapy and methods for treatment and prevention of hyperproliferative diseases | CIUSTEA MIHAI (US) | 2015-04-02 | — | — | US | disclosed |
| CN-101486668-B | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT INC | 2014-07-02 | — | — | CN | disclosed |
| US-20130045179-A1 | Combination therapy and methods for treatment and prevention of hyperproliferative diseases | CIUSTEA MIHAI (US) | 2013-02-21 | — | — | US | disclosed |
| CN-102775396-A | Modulators of ATP-binding cassette transporters | VERTEX PHARMA | 2012-11-14 | — | — | CN | disclosed |
| CN-102702065-A | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT INC | 2012-10-03 | — | — | CN | disclosed |
| CN-101356170-B | Heterocyclic modulators of ATP-binding cassette transporters | VERTEX PHARMA | 2012-09-26 | — | — | CN | disclosed |
| EP-2387575-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | Anvyl, LLC (US) | 2011-11-23 | — | — | EP | disclosed |
| US-D647030-S1 | Automobile tire tread | THE YOKOHAMA RUBBER CO., LTD (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2011092284-A1 | NOVEL AMINO ACID DERIVATIVES AND THEIR USE AS GPR43 RECEPTOR MODULATORS | EUROSCREEN S.A. (BE) | 2011-08-04 | — | — | WO | disclosed |
| CN-101914040-A | Acyloxyalkyl carbamate prodrugs, synthetic method and purposes | XENOPORT INC | 2010-12-15 | — | — | CN | disclosed |
| CN-1860101-B | Acyloxyalkyl carbamate prodrugs, synthesis methods and uses | XENOPORT INC | 2010-10-27 | — | — | CN | disclosed |
| CN-1860101-B | Acyloxyalkyl carbamate prodrugs, synthesis methods and uses | XENOPORT INC | 2010-10-27 | — | — | CN | disclosed |
| CN-101486668-A | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT INC (US) | 2009-07-22 | — | — | CN | disclosed |
| US-20090082435-A1 | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-01 | — | — | US | disclosed |
| EP-1523982-B1 | Plenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders | US GOV HEALTH & HUMAN SERV (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | ZGENE A/S (DK) | 2007-11-15 | — | — | US | disclosed |
| CN-1902175-A | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT INC (US) | 2007-01-24 | — | — | CN | disclosed |
| US-20070015943-A1 | Method of preparation of optically active alcohols | POSTECH FOUNDATION (KR) | 2007-01-18 | — | — | US | disclosed |
| EP-1742626-A2 | COMPOUNDS AND METHODS FOR TREATING NON-INFLAMMATORY PAIN USING PPARALPHA AGONISTS | The Regents of The University of California (US) | 2007-01-17 | — | — | EP | disclosed |
| CN-1860101-A | Acyloxyalkyl carbamate prodrugs, synthesis methods and uses | XENOPORT INC (US) | 2006-11-08 | — | — | CN | disclosed |
| CN-1860101-A | Acyloxyalkyl carbamate prodrugs, synthesis methods and uses | XENOPORT INC (US) | 2006-11-08 | — | — | CN | disclosed |
| WO-2006116773-A2 | METHODS, COMPOSITIONS, AND COMPOUNDS FOR MODULATION OF MONOACYLGLYCEROL LIPASE, PAIN, AND STRESS-RELATED DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1660440-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | Xenoport, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005115370-A2 | COMPOUNDS AND METHODS FOR TREATING NON-INFLAMMATORY PAIN USING PPARALPHA AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005079849-A2 | COMPOUNDS FOR ENHANCED CANCER THERAPY | ZGENE A/S (DK) | 2005-09-01 | — | — | WO | disclosed |
| CN-1616432-A | Compound,its use and pharmaceutical compositions comprising same | ELAN PHARM INC (US) | 2005-05-18 | — | — | CN | disclosed |
| WO-2005019163-A3 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT INC (US) | 2005-04-28 | — | — | WO | disclosed |
| EP-1523982-A2 | Plenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-04-20 | — | — | EP | disclosed |
| WO-2005019163-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005009935-A1 | METHOD OF PREPARATION OF OPTICALLY ACTIVE ALCOHOLS | POSTECH FOUNDATION (KR) | 2005-02-03 | — | — | WO | disclosed |
| EP-0725635-B1 | PHENYLACETATE AND DERIVATIVES ALONE OR IN COMBINATION WITH OTHER COMPOUNDS AGAINST NEOPLASTIC CONDITIONS AND OTHER DISORDERS | US GOV HEALTH & HUMAN SERV (US) | 2004-12-29 | — | — | EP | disclosed |
| CN-1171878-C | Compounds, their use and pharmaceutical compositions containing them | ������˹ҩƷ��˾ | 2004-10-20 | — | — | CN | disclosed |
| US-20020137964-A1 | Process for the preparation of a saturated carboxylic acid ester | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2002-09-26 | — | — | US | disclosed |
| US-6365398-B1 | REACTING RACEMIC CARBOXYLIC ACID ESTER WITH RACEMIC ALCOHOL IN PRESENCE OF A CARBOXYL ESTER HYDROLASE | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
| CN-1242007-A | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising such compounds, and methods of inhibiting beta amyloid peptide release and/or its synthesis using such compounds | ELAND PHARMACEUTICAL CORP (US) | 2000-01-19 | — | — | CN | disclosed |
| US-5883124-A | ADMINISTERING PHENYLACETIC ACID DERIVATIVE AND RETINOID TO TREAT TUMORS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-03-16 | — | — | US | disclosed |
| US-5852056-A | Phenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-12-22 | — | — | US | disclosed |
| US-5843994-A | Compositions and methods for treating and preventing pathologies including cancer | THE UNITED STATES OF AMERICA AS REPRESENETED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-12-01 | — | — | US | disclosed |
| US-5712307-A | Methods of inducing the production of hemoglobin and treating pathologies associated with abnormal hemoglobin activity using phemylacetic acids and derivatives therof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-27 | — | — | US | disclosed |
| US-5710178-A | ARYL- AND ARYLOXYALKANOIC ACIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-20 | — | — | US | disclosed |
| US-5708025-A | BY INDUCING PRODUCTION OF FETAL HEMOGLOBINS BY ADMINISTERING SPECIFIED ARYL ACIDS, DERIVATIVES, SALTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-13 | — | — | US | disclosed |
| US-5661179-A | ADMINISTERING; TREATS NEUROBLASTOMA, MYELODYSPLASIA, NON-SMALL CELL LUNG CANCER, PROSTATE CANCER, MELANOMA, BRAIN TUMOR, KAPOSI'S SARCOMA, LYMPHOMA, LEUKEMIA, BREAST AND LUNG CANCER, OSTEOSARCOMA AND FIBROSARCOMA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-26 | — | — | US | disclosed |
| US-5654333-A | THERAPY FOR ANEMIA, CANCER, AIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-05 | — | — | US | disclosed |
| US-5635532-A | ADMINISTERING PHENYL OR NAPHTHYL ACETIC ACID DERIVATIVES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | disclosed |
| US-5635533-A | ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | disclosed |
| US-5605930-A | ADMINISTERING PHENYLACETIC ACID AS AN INHIBITOR OF THE MEVALONATE PATHWAY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0517876-B1 | THERAPEUTIC BENZAZEPINE COMPOUNDS | ZENECA LTD (GB) | 1996-10-23 | — | — | EP | disclosed |
| EP-0725635-A1 | PHENYLACETATE AND DERIVATIVES ALONE OR IN COMBINATION WITH OTHER COMPOUNDS AGAINST NEOPLASTIC CONDITIONS AND OTHER DISORDERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-08-14 | — | — | EP | disclosed |
| US-5541319-A | REACTING SUBSTITUTED BENZAZEPINE ETHER WITH BORON TRIHALIDE TO FORM HYDROXY GROUP, FORMING SALT WITH BASE IF DESIRED | ZENECA LIMITED (GB) | 1996-07-30 | — | — | US | disclosed |
| US-5446039-A | Treating nervous system and brain disorder, acting as excitatory amino acid antagonist | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1995-08-29 | — | — | US | disclosed |
| WO-1995010271-A2 | PHENYLACETATE AND DERIVATIVES ALONE OR IN COMBINATION WITH OTHER COMPOUNDS AGAINST NEOPLASTIC CONDITIONS AND OTHER DISORDERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-04-20 | — | — | WO | disclosed |
| EP-0294220-B1 | Photopolymerizable composition | HITACHI CHEMICAL CO LTD (JP) | 1994-05-25 | — | — | EP | disclosed |
| US-5254683-A | Neurological disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-19 | — | — | US | disclosed |
| US-5190946-A | Piperazine compounds restore sensitivity to drug resistant cancer cells | HOFFMANN-LA ROCHE INC. (US) | 1993-03-02 | — | — | US | disclosed |
| EP-0517876-A1 | THERAPEUTIC BENZAZEPINE COMPOUNDS. | ICI PLC (GB) | 1992-12-16 | — | — | EP | disclosed |
| WO-1992011854-A1 | THERAPEUTIC BENZAZEPINE COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-23 | — | — | WO | disclosed |
| US-5089639-A | N-CYCLOALKYLALKYLAMINES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT AND THEIR SYNTHESIS INTERMEDIATES | JOUVEINAL S.A. (FR) | 1992-02-18 | — | — | US | disclosed |
| EP-0443569-A2 | Diamine derivatives and their use in oncology | F. HOFFMANN-LA ROCHE AG (CH) | 1991-08-28 | — | — | EP | disclosed |
| US-5034429-A | An unsaturated monomer, a photoinitiator and a benzene derivative for providing a cured film | HITACHI CHEMICAL CO., LTD. (JP) | 1991-07-23 | — | — | US | disclosed |
| EP-0218368-B1 | IMPROVEMENTS RELATING TO PESTICIDES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-06-13 | — | — | EP | disclosed |
| US-4874781-A | INSECTICIDES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1989-10-17 | — | — | US | disclosed |
| EP-0294220-A2 | Photopolymerizable composition | Hitachi Chemical Co., Ltd. (JP) | 1988-12-07 | — | — | EP | disclosed |
| EP-0218368-A1 | Improvements relating to pesticides | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1987-04-15 | — | — | EP | disclosed |
| US-4540710-A | Insecticidal ester enantiomers | THE COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 1985-09-10 | — | — | US | disclosed |
| US-4391820-A | Insecticidal ester enantiomers | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 1983-07-05 | — | — | US | disclosed |
| EP-0043187-A1 | Pesticidal cyclobutyl carboxylic ester comprising compositions | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1982-01-06 | — | — | EP | disclosed |
| US-4003911-A | ANTISECRETORY AGENTS, OXYTOCICS, BRONCHODILATORS, PLASTICIZERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-01-18 | — | — | US | disclosed |
| US-3968124-A | Process for preparing phenyl-acetic acid esters | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1976-07-06 | — | — | US | disclosed |
| US-3968124-A | Process for preparing phenyl-acetic acid esters | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295652-A1 | Inhibitors of Molluscum Contagiosum Infection and Methods Using the Same | ITCH, EIF2AK2, TBK1 | POLB 1477/4885CYP2C9 4632/4885CYP2C19 4664/4885 |
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | FAAH, CNR2, FAAH2 | POLB 2082/4885CYP2C9 1534/4885CYP2C19 1568/4885 |
| US-20250352498-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING PHENYLBUTYRATE AND METHODS THEREOF | ABAT, CPT1B, GABBR1 | POLB 1625/4885CYP2C9 618/4885CYP2C19 451/4885 |
| US-11873267-B2 | Functionalized N,N-dialkylamino phenyl ethers and their method of use | GAA, GBA1, GBA2 | POLB 2340/4885CYP2C9 2643/4885CYP2C19 1557/4885 |
| US-20090082435-A1 | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders | MGLL, PNLIP, LIPC | POLB 2270/4885CYP2C9 2756/4885CYP2C19 2585/4885 |
| US-20240246904-A1 | FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | GAA, GBA1, GBA2 | POLB 2340/4885CYP2C9 2643/4885CYP2C19 1557/4885 |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | TYMP, BAD, NUDT1 | POLB 524/4885CYP2C9 2291/4885CYP2C19 1217/4885 |
| US-20020137964-A1 | Process for the preparation of a saturated carboxylic acid ester | ADH1C, ADH1A, ADH5 | POLB 156/4885CYP2C9 347/4885CYP2C19 208/4885 |
| US-20200392073-A1 | NOVEL FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | GAA, GBA1, GBA2 | POLB 2735/4885CYP2C9 3389/4885CYP2C19 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.